Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B

NCT05871749 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-07-31

No results posted yet for this study

Summary

The investigator aimed to prospectively study the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ATI value) in patients with chronic hepatitis B.

Conditions

Sponsors & Collaborators

  • Canon Medical Systems, Korea

    collaborator UNKNOWN
  • So Yeon Kim

    lead OTHER

Principal Investigators

  • Soyeon Kim, Professor · Asan Medical Center

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-07
Primary Completion
2024-02-16
Completion
2024-06-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05871749 on ClinicalTrials.gov